Generics Hit Home
by Laura Whitehorn
Last December, the FDA gave Barr Laboratories approval to sell the U.S.’ first generic HIV med, didanosine delayed-release capsules, the equivalent of BMS’s nuke Videx EC (but about $1.70 less per pill). HIV generics, available in the developing world thanks to international economic agreements, have been blocked here by name-brand patents. But some of those are now running out (AZT’s ends this year), foretelling more off-brand HAART.